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Abstract
Background: Tissue inhibitors of metalloproteinases (TIMPs) and the corresponding metalloproteinases are integral
parts of the protease network and have been shown to be involved in cancer development and metastasis.
Paradoxically, for TIMP-1, tumor promoting as well as tumor inhibitory effects have been observed.
Methods: To address this paradox, we utilized the BALB/c/CT26 mouse model that reliably leads to liver metastasis
after splenic tumor cell injection and variegated the type of target cells for therapeutic intervention and the
modalities of gene transfer. Since we have observed before that over-expression of TIMP-1 in liver host cells leads
to efficient tumor growth inhibition in this model, we now examined whether targeting the tumor cells
themselves will have a similar effect.
Results: In concordance with the earlier results, TIMP-1 over-expression in tumor cells led to a dramatic reduction
of tumor growth as well. To evaluate any influence of treatment modality, we further examined whether TIMP-1
knockdown in the same animal model would have the opposite effect on tumor growth than TIMP-1 over-
expression. Indeed, TIMP-1 knockdown led to a marked increase in tumor burden.
Conclusion: These data indicate that in the BALB/c/CT26 model, the modification of TIMP-1 has concordant effects
irrespective of the type of target cell or the technique of modulation of TIMP-1 activity, and that TIMP-1 is
unequivocally tumor inhibitory in this model.
Background
Colorectal carcinoma is the second most frequent can-
cer disease in both sexes [1]. For patients with this type
of cancer, liver metastases are the main cause of death.
They often remain the only manifestation of the disease
once the primary tumor has been surgically removed
[2,3].
Therefore, successful treatment of liver metastases has
the potential to cure the patient, and thus this is an area
under intensive investigation. Besides standard treat-
ment modalities like surgical intervention and che-
motherapy, a number of molecular-based approaches for
the treatment of colorectal liver metastases have been
examined during the last 2 decades [4]. Among those, a
modulation of the cancer cells’ microenvironment has
gained increasing interest [5-7], because a permissive
host environment at the primary invasive site as well as
at the site of metastasis is a prerequisite for successful
tumor cell invasion.
Which are the potential target molecules? Excessive
degradation and remodeling of the extracellular matrix
(ECM) is one of the hallmarks of cancer progression at
nearly every step of the metastatic cascade. Proteases
contribute to each step from the first breakdown of the
basal membrane of the primary tumor up to the
extended growth of established metastases [8]. Among
others, matrix metalloproteinases (MMPs) are a family
of 24 enzymes that play an important role in this
process. Naturally occurring tissue inhibitors of metallo-
proteinases (TIMPs 1 to 4) normally regulate and coun-
terbalance the proteolytic activity of MMPs by binding
to both the latent and active forms of MMPs in a 1:1
stoichiometry [9,10]. Consequently, over-expression of
TIMPs by means of gene transfer [11-13] as well as by
* Correspondence: karsten.brand@med.uni-heidelberg.de
Institute of Pathology, University Hospital Heidelberg, University of
Heidelberg, Im Neuenheimer Feld 220/1, 69120 Heidelberg, Germany
Bandapalli et al. BMC Research Notes 2012, 5:14
http://www.biomedcentral.com/1756-0500/5/14
© 2011 Bandapalli et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.application of synthetic MMP inhibitors [13] has shown
marked antitumor activity in various animal models.
However, contradictory tumor growth promoting effects
of TIMPs 1 to 3 have been reported in vitro, which
occasionally translated into promotion of cell growth
and metastasis in vivo (for review [13]). In addition,
clinical trials using synthetic MMP inhibitors were of
limited success [14]. These conflicting data indicate that
a deeper understanding of the MMP/TIMP interplay
and of potential additional functions is required. It
appears as if only a fairly comprehensive understanding
of the proteolytic network will finally allow the develop-
ment of MMP specific inhibitors and will allow for the
judgment of which situations they can be applied to (for
review [15]).
To contribute another brick to the protease network
and to help clarify conflicting data, we have utilized the
BALB/c/CT26 animal model for colorectal liver metas-
tases that exhibits reliable and reproducible liver metas-
tases upon splenic injection of tumor cells [12,16]. In
this study, we examined by means of gene transfer
whether the type of target cell or the modality of gene
expression modification will have an effect on TIMP-1’s
putative growth-promoting or -inhibitory function. Our
data indicate that TIMP-1 in our model exhibits unequi-
vocal effects, because it is tumor protective irrespective
of whether host cells or tumor cells are targeted and
irrespective of whether knockdown technology or over-
expression technology is used.
Methods
Cell lines and animal experiments
CT26 human colon adenocarcinoma cells were cultured
in RPMI supplemented with 10% FCS, 2 mM glutamine,
100 IU/mL penicillin, and 50 mg/mL streptomycin.
Liver metastases were induced in 6 to 8-week-old
BALB/c mice by intrasplenic injection of tumor cells.
Briefly, a small upper quadrant incision was used to
expose the spleen, and 1 × 10
6 cells in 50 μlw e r e
injected into the lower splenic pole with a 30.5 gauge
needle. The spleen was returned to the abdominal cav-
ity, the peritoneum was closed by suture, and the skin
with wound clips. Two weeks after tumor cell inocula-
tion, the animals were sacrificed, and total liver weights
were determined. Animal experiments were performed
according to official guidelines, with permission (by
regional board Karlsruhe) under File No. 35-9185.81/G-
50/05.
Tissue preparation, laser microdissection (LMD) and
microarray hybridization
Frozen tissue blocks were cut into 15 μm sections using
a cryostat (Leica, Wetzlar, Germany) and stained using
cresyl violet, according to the Ambion LCM staining kit
protocol (Austin, TX, USA). Four distinct cell popula-
tions were separately microdissected with LCM equip-
ment (Molecular Machines & Industries, Eching,
Germany; or PALM, Bernried, Germany): (a) pure liver
tissue, at least 5 cm away from the invasive front; (b)
liver invasive front tissue, extending up to 10 cell layers
into the liver; (c) tumor invasive front tissue, extending
up to 10 cell layers into the tumor; and (d) pure tumor
tissue, at least 100 cell layers away from the invasive
front. These compartments were arbitrarily selected due
to prior experience and results from immunostaining of
up-regulated genes (unpublished data). Microdissection
was performed to yield sufficient material for microarray
and qPCR analysis.
Total RNA from microdissected samples was extracted
(RNeasy mini kit; Qiagen, Hilden, Germany), and quality
was evaluated using an Agilent 2100 bioanalyzer (Wald-
bronn, Germany). For microarray analysis, 30 ng of RNA
corresponding to 2500-3500 cells from each microdis-
sected group were amplified (RiboAmp HS RNA amplifi-
cation kit; Arcturus, Sunnyvale, CA, USA), labeled, and
the resulting biotinylated cRNA targets were used to
probe the murine genome MOE430 set (A + B) (Affyme-
trix, Santa Clara, CA). Hybridization was performed in
duplicates. Altogether, 8 chips were hybridized (2 com-
partments × 2 sub-chips [A + B] × 2 [duplicates] = 8).
For estimation of the percentage of tumor tissue as
compared to pre-existent liver parenchyma, whole livers
were embedded in paraffin and hematoxylin/eosin
stained according to standard procedures.
Data analysis
Raw files (cel files) from the scanned images of the Affy-
metrix chips (run in duplicates) were normalized using
Affymetrix GCOS software, and fold changes were cal-
culated using Excel (Microsoft, Seattle, USA) software.
Relative quantitative real time-PCR
Microdissection and RNA isolation for relative qPCR
were essentially performed as for hybridization experi-
ments; however, independent samples were used. Thirty
nanograms of total RNA, corresponding to 2500-3500
cells were used for quantification. Reverse transcription,
qPCR, normalization (on 18S RNA), and efficiency cor-
rection (on 18S RNA) were performed. Oligonucleotides
for 18S RNA and IL-8 qPCR were designed using the
Primer3 software (Whitehead Institute, Cambridge, MA,
USA). The sequences for 18S RNA were as follows: for-
ward primer, 5’-AAA CGG CTA CCA CAT CCA AG-
3’; reverse primer, 5’-CCT CCA ATG GAT CCT CGT
TA-3’. Primers for TIMP-1 were purchased (Cat No.
QT00996282; QuantiTect
® primers, Qiagen GmbH, Hil-
den, Germany). All the experiments were done in tripli-
cate and repeated twice.
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Cells were transfected with pSM2C plasmids containing
2 different TIMP-1 shRNAmir constructs (TIMP-1
ShRNA-317 and TIMP-1 ShRNA-234) (Open Biosys-
tems, AL, Huntsville, USA) or a non-silencing shRNA-
mir construct, according to the manufacturer’s
instructions. Briefly, 2 × 10
5 CT-26 cells were seeded
into 6 well plates and subsequently transferred using
Arrest-In
™ transfection reagent (Open Biosystems) with
the indicated shRNAmir (10 μg transfection solution
containing 2 μgT I M P - 1s h R N A m i ro r2μgc o n t r o l
siRNA). After 6 h, the medium was replaced by standard
culture medium. The cells were returned to the CO2
incubator at 37°C. Forty-eight hours later, the cells were
grown in a complete medium supplemented with puro-
mycin (2 μg/mL) for selection. Single clones were then
selected from pooled populations by serial dilutions
using standard protocols. Successful shRNA transfection
was confirmed by qRT-PCR and ELISA. All the experi-
ments were performed in triplicates and repeated twice.
Over-expression of TIMP-1
Lentiviral TIMP-1 viruses (LvhuTIMP-1) were generated
by co-transfection of pLenti6/V5-DESThuTIMP-1 vector
containing human TIMP-1 under the control of the
CMV promoter with the ViraPower
™ packaging plasmid
mixture: pLP1, pLP2, and pLP/VSV-G (Invitrogen) into
293FT cells using Lipofectamine 2000 (Invitrogen).
CT26 cells were infected with LvhuTIMP-1 viruses and
transduced cells were selected by blasticidin (5 μg/mL).
ELISA
Enzyme-linked immunosorbent assay (ELISA) was used
to determine the concentration of TIMP-1 in TIMP-1
over-expressing and down-regulated cells compared to
the wild type control cells and non-coding shRNA con-
trol cells using Quantikine human and mouse TIMP-1
assay kit according to the manufacturer’s instructions
(R&D systems, Wiesbaden, Germany). All the experi-
ments were performed in triplicates and repeated twice.
Statistical analysis and software
Data are presented as the mean ± standard deviation.
The statistical comparison between groups of animal
experiments was accomplished with the non-parametric
Wilcoxon test.
Results
TIMP-1 is expressed in liver parenchyma and tumor
compartments
We first wanted to examine to what extent TIMP-1 is
expressed in our animal model. In particular, we wanted
to know, whether there is differential gene expression
between different compartments of colorectal liver
metastases, namely between the liver part of the inva-
sion front (LI), liver away from the invasion front (L),
tumor part of the invasion front (TI), and tumor away
from the invasion front (T). As displayed in Figure 1,
TIMP-1 mRNA levels in LI were 4-fold higher than in L
a n d2 . 9 - f o l dh i g h e ri nT It h a ni nT .T h er a t i oo fp u r e
tumor tissue to pure liver tissue was 3.2 to 1. The high-
est TIMP-1 levels were observed in TI, which were 9.1-
fold higher than that in L. These data indicate that
TIMP-1 is expressed in the tumor as well as in the liver,
and that the invasion front compartments exhibit higher
TIMP-1 levels than the inner parts of liver and tumor
respectively.
Construction of TIMP-1 knockdown and TIMP-1 over-
expressing cells
In the next step, we constructed genetically modified
cell lines to examine putative anti-metastatic TIMP-1
activity in vivo. We have earlier shown that adenoviral
gene transfer of TIMP-1 [12] or TIMP-2 [11] into the
unaffected liver tissue of mice can inhibit the growth of
colorectal liver metastases. Since adenoviral gene trans-
fer specifically targets the liver cells including hepato-
cytes, hepatic stellate cells, and macrophages, the
observed antitumor effect was due to TIMP-1 expres-
sion by host cells. We now wanted to examine whether
targeting of the tumor cells would lead to an antitumor
effect as well. To this extent, CT26 cells were stably
transduced with human TIMP-1 cDNA under the con-
trol of the CMV promoter. Production of human TIMP-
0
2
4
6
8
10
LL I T IT
Compartment
T
I
M
P
-
1
e
x
p
r
e
s
s
i
o
n
p=0.001
p=0.005
Figure 1 Gene expression of TIMP-1 in 4 different
compartments of mouse livers harboring colorectal liver
metastases. Bars represent fold changes of TIMP-1 mRNA with the
values obtained in pure liver tissue set as baseline. L, liver tissue; LI,
liver part of the invasion front; TI, tumor part of the invasion front; T,
tumor tissue.
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(Figure 2A). Whereas no human TIMP-1 could be
detected in wild type murine CT26 cells, a concentra-
tion of 4.2 ng/mL could be detected in the supernatants
of TIMP-1 over-expressing cells.
In a second approach, we wanted to examine whether
knockdown of endogenous TIMP-1 would lead to the
opposite in vivo effect than over-expression of TIMP-1.
To this extent, CT26 colon carcinoma cells were stably
transduced with TIMP-1 shRNA or control shRNA, and
TIMP-1 mRNA levels as well as protein levels were
determined by semi-quantitative RT-PCR and ELISA,
respectively. The best clone displayed a reduction of
TIMP-1 mRNA by 90% (Figure 2C) and of TIMP-1 pro-
tein by 65% (Figure 2B). A fairly strong and apparently
unspecific reduction of TIMP-1 mRNA and protein was
observed if scrambled control RNA was used.
TIMP-1 knockdown and TIMP-1 over-expression lead to
opposite effects on metastatic tumor growth
To evaluate whether TIMP-1 over-expression by tumor
cells will have an anti-metastatic effect like over-expres-
sion by stromal cells [12] and to evaluate whether
knockdown of endogenous TIMP-1 will have the oppo-
site effect, we applied the CT26 TIMP-1 over-expressing
cells or CT26 TIMP-1 knockdown cells into the spleens
of BALB/c mice and allowed liver metastases to develop.
After 14 days, animals were sacrificed, and liver weights
were determined. Over-expression of TIMP-1 led to a
significant reduction of tumor burden, as compared to
the wild type and the scrambled shRNA control groups
(Figure 3A-C). In contrast, TIMP-1 knockdown
increased tumor burden dramatically. Differences were
significant with regard to both examined parameters:
total liver weights (Figure 3A) and percentage of tumor
as compared to pre-existent liver parenchyma (Figure
3C). No notable difference between wild type control
cells and scrambled shRNA control cells was observed.
Discussion and conclusions
In this study, we examined the effect of targeting tumor
cells by modulation of TIMP-1 gene expression for the
treatment of colorectal liver metastases. We observed a
pronounced inhibition of tumor growth if TIMP-1 was
over-expressed and a pronounced increase of tumor
growth if TIMP-1 was knocked down.
The inhibition of tumor growth upon over-expression
of TIMP-1 is concordant with our earlier observation in
the same animal model of an inhibition of liver metas-
tases if the liver host cells are targeted by adenoviral
gene transfer [12]. In fact, the degree of tumor growth
inhibition was even comparable as being roughly 2.5 to
4-fold in both studies. This result indicates that TIMP-1
exerts its metastasis inhibitory effect irrespective of
whether the host microenvironmental cells or the tumor
cells are targeted. Apparently, in both cases, sufficient
amounts of TIMP-1 are secreted to act in a paracrine
fashion to inhibit ECM-degrading MMPs. In addition, it
appears as if the mere quantity of TIMP-1 expression is
a decisive parameter to observe any in vivo effects. We
have earlier observed that only high levels of TIMP-1
but not moderate levels expressed by host cells had an
anti-tumor effect [12]. Similarly, in this current study,
only a prominent reduction of TIMP-1 levels in the
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Figure 2 Over-expression and knockdown of TIMP-1 in CT-26
murine colon carcinoma cells.(A) Secretion of human TIMP-1 by
stably TIMP-1-transduced cells (ELISA). (B, C) Secretion of murine
TIMP-1 protein (B, ELISA) or expression of TIMP-1 mRNA (C, relative
qPCR) by wild type cells or by stable clones harboring TIMP-1
shRNA or non-coding (NTC) shRNA.
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Figure 3 Effect of over-expression and knockdown of TIMP-1 on tumor growth in vivo.( A) Bars represent liver weights of BALB/c mice
challenged with splenic injections of wild type and modified CT26 cells as indicated. The whole experiment was terminated, when the first
animal had to be euthanized due to ethical guidelines. +: mean. (B) Photograph of resected livers. Any increase in liver weight is due to an
increase in tumor burden. (C) Percentage of tumor tissue (area) as compared to pre-existent liver parenchyma.
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NCT control group had any effect on tumor growth.
The antitumor effect of TIMP-1 is in agreement with
a number of studies reporting decreased numbers and
sizes of primary tumors and metastases upon TIMP-1
over-expression (for review [13]), including stomach
cancer [17], melanoma [18], fibrosarcoma [19], and
pancreatic cancer [20]). These effects argue in favor of
a dominant antitumor effect of TIMP-1 in our model
over any putative growth-promoting effects. In con-
trast, in a model of lymphoma and fibrosarcoma meta-
static to the liver, moderate over-expression of TIMP-1
in transgenic mice did not change metastasis [21,22],
whereas adenoviral gene transfer, which leads to very
high levels of TIMP-1, had a pronounced anti-meta-
static effect [12]. One reason for these conflicting data
may be that only prominent modifications of TIMP-
levels will have effects on tumor growth, whereas
minor modifications can bec o m p e n s a t e df o rb yt h e
tumor. Another reason may be profound inherent dif-
ferences in the model systems.
Our studies on over-expression of TIMP-1 were per-
formed with human TIMP-1. We were now interested
to examine whether knockdown of endogenous murine
TIMP-1 would have the expected opposite effect as
over-expression of human TIMP-1. Indeed, the knock-
down of endogenous murine TIMP-1 led to a dramatic
and highly significant increase of tumor burden. To our
knowledge, this is the first report of an in vivo effect of
shRNA-mediated TIMP-1 knockdown. However, related
studies underscore our findings: The knockdown of
TIMP-1 in HeLa, C33A, and A549 cancer cells [23] as
well as in corneal epithelial cells derived from pterygia
[24] increased invasion and migration.
Since our gene expression studies revealed an increase
of TIMP-1 gene expression in the invasion front we
asked ourselves why further over-expression of TIMP-1
would lead to decreased tumor growth and why knock-
down of TIMP-1 would lead to enhanced tumor growth
as we observed? One explanation among others may be
that a finely tuned balance of MMPs and TIMPs causing
increased TIMP-1 in response to increased MMP is
necessary in the active area of the invasion front,
whereas in the inner parts of the tumor unrestricted
MMP activity is more beneficial for rapid tumor growth.
In summary, our data indicat eaf a i r l yu n e q u i v o c a l
anti-metastatic effect of TIMP-1 in our animal model.
Any indications of an in vivo growth-promoting effect
that has been reported before were not seen in our sys-
tem. Targeting tumor cells appears to be at least as effi-
cient as targeting the host microenvironment, and over-
expression of human TIMP-1 has the opposite effect as
knockdown of endogenous murine TIMP-1. Altogether,
this study indicates that over-expression of TIMP-1 may
be a treatment modality for colorectal liver metastases
at least in selected situations.
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